Chelating systems for 99mTc/188Re in the development of radiolabeled peptide pharmaceuticals

Anti-Cancer Agents in Medicinal Chemistry

Volumn 12, Issue 5, 2012, Pages 428-461

  Bolzati, Cristina ^a   Carta, Davide ^b   Salvarese, Nicola ^b   Refosco, Fiorenzo ^a  

^a CNR   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

Author keywords

Peptide; Rhenium; Technetium; Theragnostic

Indexed keywords

2 METHOXYPHENYLPIPERAZINE; ANGIOPEPTIN; APCITIDE TC 99M; ARCITUMOMAB TC 99M; ARGINYLGLYCYLASPARTIC ACID; BOMBESIN DERIVATIVE; CEASCAN; COPPER 64; DEMOBESIN; DEPREOTIDE TC 99M; DISULFIDECYCLIZED OCTREOTIDE; DITHIOCARBAMIC ACID; DITHIOCARBAZATE; FLUORINE 18; INDIUM 111; LUTETIUM 177; MACROGOL 6000; MINIGASTRIN; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; NEUROTENSIN; NITRIDO RE 188; OCTREOTIDE RE; PENTETIC ACID; RADIOPHARMACEUTICAL AGENT; RHENIUM 188; SULESOMAB TC 99M; TECHNETIUM 99M; UNCLASSIFIED DRUG; UNINDEXED DRUG; VAPREOTIDE; VAPREOTIDE RE 188; YTTRIUM 90;

AMINO ACID SEQUENCE; BINDING AFFINITY; CANCER RADIOTHERAPY; CHELATION; COMPUTER ASSISTED TOMOGRAPHY; CYCLIZATION; DEEP VEIN THROMBOSIS; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG HALF LIFE; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG TARGETING; FOOD AND DRUG ADMINISTRATION; HIGH THROUGHPUT SCREENING; HUMAN; IC 50; ISOTOPE LABELING; LIVER CELL CARCINOMA; MAXIMUM TOLERATED DOSE; MELANOMA; MOLECULAR IMAGING; NONHUMAN; NUCLEAR MEDICINE; PEPTIDE SYNTHESIS; PHYSICAL CHEMISTRY; POSITRON EMISSION TOMOGRAPHY; PROSTATE ADENOCARCINOMA; RADIOCHEMISTRY; RECEPTOR BINDING; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

EID: 84861653577     PISSN: 18715206     EISSN: 18755992     Source Type: Journal    
DOI: 10.2174/187152012800617821     Document Type: Review

References (316)

1. 99mTc-Radiolabelled peptides for tumour imaging: present and future. Current Med Chem, 2010, 17, 2656-2683.
2. Liu, S. Bifunctional coupling agents for radiolabeling of biomolecules and target-specific delivery of metallic radionuclides. Adv Drug Deliver Rev, 2008, 60, 1347-1370.
3. 188Re-pharmaceuticals. Adv Drug Deliver Rev, 2008, 60, 1389-1401.
4. Volkert, W. A.; Hoffman, T. J. Therapeutic radiopharmaceuticals. Chem Rev, 1999, 99, 2269-2292.
5. McEwan, A. J. B. Unsealed source therapy of painful bone metastases: An update. Semin Nucl Med, 1997, 27, 165-182.
6. Gregoire, V.; Bol, A.; Geets, X.; Lee, J. Is PET-based treatment planning the new standard in modern radiotherapy? The head and neck paradigm. Semin Radiat Oncol, 2006, 16, 232-238.
7. Bentzen, S. M. Theragnostic imaging for radiation oncology: dosepainting by numbers. Lancet Oncol, 2005, 6, 112-117.
8. Weissleder, R. Molecular imaging: Exploring the next frontier. Radiology, 1999, 212, 609-614.
9. Herschman, H. R. Molecular imaging: Looking at problems, seeing solutions. Science, 2003, 302, 605-608.
10. Kassis, A. I.; Adelstein, J., Considerations in the selection of radionuclides for cancer therapy. M.J. Welch, C.S. Redvanly (Eds.) Handbook of Radiopharmaceuticals, Radiochemistry and Applications, Wiley & Sons, London: 2003, 767-793.
11. Pasqualini R. Present-day development of Tc-99m radiopharmaceuticals an economic challenge for pharmaceutical companies. The IBA involvment. In Technetiun and Other Metals in Chemistry and Medicine, eds Mazzi U. Eckelman W. C. and Volkert W. A. SGEditoriali, Padova, Italy, 2010, 513-516.
12. Rowland, D. J.; Cherry, S. R. Small-animal preclinical nuclear medicine instrumentation and methodology. Semin Nucl Med, 2008, 38, 209-222.
13. Del Guerra, A.; Belcari, N. State-of-the-art of PET, SPECT and CT for small animal imaging. Nucl Instrum Meth A, 2007, 583, 119-124.
14. Mariani, G.; Bruselli, L.; Duatti, A. Is PET always an advantage versus planar and SPECT imaging? Eur J Nucl Med Mol Imaging, 2008, 35, 1560-1565.
15. Townsend, D. W. Dual-modality imaging: Combining anatomy and function. J Nucl Med, 2008, 49, 938-955.
16. Buck, A. K.; Nekolla, S.; Ziegler, S.; Beer, A.; Krause, B. J.; Herrmann, K.; Scheidhauer, K.; Wester, H. J.; Rummeny, E. J.; Schwaiger, M.; Drzezga, A. SPECT/CT. J Nucl Med, 2008, 49, 1305-1319.
17. Franc, B. L.; Acton, P. D.; Mari, C.; Hasegawa, B. H. Small-Animal SPECT and SPECT/CT: Important Tools for Preclinical Investigation. J Nucl Med, 2008, 49, 1651-1663.
18. Rollo, F. D. Molecular imaging: an overview and clinical applications. Radiol Manage, 2003, 25, 28-32.
19. Kunstler, J. U.; Seidel, G.; Pietzsch, H. J. Efficient preparation of Tc-99m(III) '4+1' mixed-ligand complexes for peptide labeling with high specific activity. Appl Radiat Isotopes, 2010, 68, 1728-1733.
20. Eckelman, W. C.; Erba, P. A.; Schwaiger, M.; Wagner, H. N.; Alberto, R.; Mazzi, U. Postmeeting summary on the round table discussion at the Seventh International Symposium on Technetium in Chemistry and Nuclear Medicine held in Bressanone, Italy on Sept 6-9, 2006. Nucl Med Biol, 2007, 34, 1-4.
21. Bartholoma, M. D.; Louie, A. S.; Valliant, J. F.; Zubieta, J. Technetium and Gallium Derived Radiopharmaceuticals: Comparing and Contrasting the Chemistry of Two Important Radiometals for the Molecular Imaging Era. Chem Rev, 2010, 110, 2903-2920.
22. Knapp, F. F.; Callahan, A. P.; Beets, A. L.; Mirzadeh, S.; Hsieh, B. T. Processing of Reactor-Produced W-188 for Fabrication of Clinical-Scale Alumina-Based W-188/Re-188 Generators. Appl Radiat Isotopes, 1994, 45, 1123-1128.
23. Deutsch, E.; Libson, K.; Vanderheyden, J. L.; Ketring, A. R.; Maxon, H. R. The Chemistry of Rhenium and Technetium as Related to the Use of Isotopes of These Elements in Therapeutic and Diagnostic Nuclear-Medicine. Nucl Med Biol, 1986, 13, 465-477.
24. Volkert, W. A.; Hoffman, T. J. Therapeutic radiopharmaceuticals. Chem Rev, 1999, 99, 2269-2292.
25. Seifert, S.; Heinrich, T.; Jentschel, C.; Smuda, C.; Bergmann, R.; Pietzsch, H. J. Preparation and biological characterization of isomeric Re-188(V) oxocomplexes with tetradentate S-4 ligands derived from meso-dimercaptosuccinic acid for labeling of biomolecules. Bioconjug Chem, 2006, 17, 1601-1606.
26. Seifert, S.; Pietzsch, H. J. The Re-188(III)-EDTA complex-a multipurpose starting material for the preparation of relevant Re-188 complexes under mild conditions. Appl Radiat Isotopes, 2006, 64, 223-227.
27. -: Efficient synthesis of Re-188(V)-meso-2,3-dimercaptosuccinic acid. Nucl Med Biol, 2000, 27, 309-314.
28. 4 chelates for labeling biomolecules. Nuklearmedizin-Nuclear Medicine, 2007, 46, 181-184.
29. Seifert, S.; Kunstler, J. U.; Schiller, E.; Pietzsch, H. J.; Pawelke, B.; Bergmann, R.; Spies, H. Novel procedures for preparing Tc-99m(III) complexes with tetradentate/monodentate coordination of varying lipophilicity and adaptation to Re-188 analogues. Bioconjug Chem, 2004, 15, 856-863.
30. -. Nucl Med Biol, 2003, 30, 381-387.
31. Lee, S.; Xie, J.; Chen, X. Peptides and Peptide Hormones for Molecular Imaging and Disease Diagnosis. Chem Rev, 2010, 110, 3087-3111.
32. Krohn, K. A. The physical chemistry of ligand-receptor binding identifies some limitations to the analysis of receptor images. Nucl Med Biol, 2001, 28, 477-483.
33. Reubi, J. C. Peptide Receptors as Molecular Targets for Cancer Diagnosis and Therapy. Endocr Rev, 2003, 24, 389-427.
34. Weiner, R. E.; Thakur, M. L. Radiolabeled peptides in the diagnosis and therapy of oncological diseases. Appl Radiat Isotopes, 2002, 57, 749-763.
35. Benedetti, E.; Morelli, G.; Accardo, A.; Mansi, R.; Tesauro, D.; Aloj, L. Criteria for the design and biological characterization of radiolabeled peptide-based pharmaceuticals. Biodrugs, 2004, 18, 279-295.
36. Aloj, L.; Morelli, G. Design, synthesis and preclinical evaluation of radiolabeled peptides for diagnosis and therapy. Curr Pharm Design, 2004, 10, 3009-3031.
37. McAfee, J. G.; Neumann, R. D. Radiolabeled peptides and other ligands for receptors overexpressed in tumor cells for imaging neoplasms. Nucl Med Biol, 1996, 23, 673-676.
38. Schottelius, M.; Wester, H. J. Molecular imaging targeting peptide receptors. Methods, 2009, 48, 161-177.
39. Guozheng, L.; Hnatowich, D. J. Labeling Biomolecules with Radiorhenium-a Review of the Bifunctional Chelators. Anticancer Agents Med Chem, 2007, 7, 367-377.
40. Deutsch, E.; Libson, K.; Vanderheyden, J.-L. The inorganic chemistry of technetium and rhenium as relevant in nuclear medicine. In Technetiun and Rhenium in Chemistry and Nuclear Medicine 3, Nicolini M., Bandoli, G. Mazzi U. eds Cortina International, Verona, Italy, 1990, 13-22.
41. 99mTc. Q J Nucl Med, 1996, 40, 221-233.
42. Mather, S. J.; Ellison, D.; Bard, D. S. Technetium-99m labelled hybrid receptor-binding peptides. In: Technetium and Rhenium in Chemistry and Nuclear Medicine 4. Nicolini M, Bandoli G, Mazzi U, eds. Padua: S.G. Editorial, 1995, 491-497.
43. Greenland, W. E. P.; Howland, K.; Hardy, J.; Fogelman, I.; Blower, P. J. Solid-phase synthesis of peptide radiopharmaceuticals using Fmoc-N-epsilon-(Hynic-Boc)-Lysine, a technetium-binding amino acid: Application to Tc-99m-labeled salmon calcitonin. J Med Chem, 2003, 46, 1751-1757.
44. Delmon-Moingeon, L. I.; Mahmood, A.; Davison, A.; Jones, A. G. Strategies for labeling monoclonal antibodies and antibody-like molecules with technetium-99m. Nucl Biol Med, 1991, 18, 47-59.
45. Rhodes, B. A. Direct Labeling of Proteins with Tc-99m. Nucl Med Biol, 1991, 18, 667-676.
46. Eckelman, W. C.; Steigman, J. Direct Labeling with Tc-99m. Nucl Med Biol, 1991, 18, 3-7.
47. Griffiths, G. L.; Goldenberg, D. M.; Jones, A. L.; Hansen, H. J. Radiolabeling of Monoclonal-Antibodies and Fragments with Technetium and Rhenium. Bioconjug Chem, 1992, 3, 91-99.
48. Zamora, P. O.; Rhodes, B. A. Imidazoles as Well as Thiolates in Proteins Bind Tc-99m. Bioconjug Chem, 1992, 3, 493-498.
49. Greenland, W. E. P.; Blower, P. J. Water-soluble phosphines for direct labeling of peptides with technetium and rhenium: Insights from electrospray mass spectrometry. Bioconjug Chem, 2005, 16, 939-948.
50. Jurisson, S. S. Tc and Re peptide chemistry: directlabeling. In Technetium, Rhenium and Other Metals in Chemistry and Nuclear Medicine 6. Nicolini, M., and Mazzi, U., Eds. SGEditoriali, Padova, Italy, 2002, 15-21.
51. Dadachova, E.; Mirzadeh, S. The role of tin in the direct labelling of proteins with rhenium-188. Nucl Med Biol, 1997, 24, 605-608.
52. Pimm, M. V.; Rajput, R. S.; Frier, M.; Gribben, S. J. Anomalies in Reduction-Mediated Tc-99m Labeling of Monoclonal-Antibodies. Eur J Nucl Med, 1991, 18, 973-976.
53. Varnum, J. M.; Thakur, M.; Mayo, K. H.; Jansen, S. A. Stability and conformational analysis of Tc-RC160 and Re-RC160: Experimental and theoretical analysis of the influence of metal complexation on the structural requisites for activity. J Phys Chem-Us, 1996, 100, 14630-14636.
54. 1H-NMR and Computer Modeling Conformational-Analysis. J Biol Chem, 1994, 269, 12583-12588.
55. 188Re-RC160, a directly-radiolabeled somatostatin analogue. Int J Cancer, 1996, 65, 214-220.
56. 188Re-RC160 somatostatin analog: A peptide for local/regional radiotherapy. Appl Radiat Isotopes, 1997, 48, 305-309.
57. 188Re-lanreotide: determination of radiopharmacokinetic parameters in rats. J Pharm Pharmacol, 2010, 62, 456-461.
58. Virgolini, I.; Britton, K.; Buscombe, J.; Moncayo, R.; Paganelli, G.; Riva, P. In-111-and Y-90-DOTA-lanreotide: Results and implications of the MAURITIUS trial. Semin Nucl Med, 2002, 32, 148-155.
59. Susini, C.; Buscail, L. Rationale for the use of somatostatin analogs as antitumor agents. Ann Oncol, 2006, 17, 1733-1742.
60. Virgolini, I.; Traub-Weidinger, T.; Decristoforo, C. Nuclear medicine in the detection and management of pancreatic islet-cell tumours. Best Pract Res Cl En, 2005, 19, 213-227.
61. Molina-Trinidad, E. M.; de Murphy, C. A.; Ferro-Flores, G.; Murphy-Stack, E.; Jung-Cook, H. Radiopharmacokinetic and dosimetric parameters of Re-188-lanreotide in athymic mice with induced human cancer tumors. Int J Pharm, 2006, 310, 125-130.
62. Fritzberg, A. R.; Abrams, P. G.; Beaumier, P. L.; Kasina, S.; Morgan, A. C.; Rao, T. N.; Reno, J. M.; Sanderson, J. A.; Srinivasan, A.; Wilbur, D. S.; Vanderheyden, J. L. Specific and Stable Labeling of Antibodies with Technetium-99m with a Diamide Dithiolate Chelating Agent. P Natl Acad Sci USA, 1988, 85, 4025-4029.
63. Eary, J. F.; Schroff, R. W.; Abrams, P. G.; Fritzberg, A. R.; Morgan, A. C.; Kasina, S.; Reno, J. M.; Srinivasan, A.; Woodhouse, C. S.; Wilbur, D. S.; Natale, R. B.; Collins, C.; Stehlin, J. S.; Mitchell, M.; Nelp, W. B. Successful Imaging of Malignant-Melanoma with Technetium-99m-Labeled Monoclonal-Antibodies. J Nucl Med, 1989, 30, 25-32.
64. Kasina, S.; Rao, T. N.; Srinivasan, A.; Sanderson, J. A.; Fitzner, J. N.; Reno, J. M.; Beaumier, P. L.; Fritzberg, A. R. Development and Biologic Evaluation of a Kit for Preformed Chelate Tc-99m Radiolabeling of an Antibody Fab Fragment Using a Diamide Dimercaptide Chelating Agent. J Nucl Med, 1991, 32, 1445-1451.
65. Liu, S.; Edwards, D. S. Tc-99m-Labeled small peptides as diagnostic radiopharmaceuticals. Chemical Rev, 1999, 99, 2235-2268.
66. Jurisson, S. S.; Lydon, J. D. Potential technetium small molecule radiopharmaceuticals. Chemical Rev, 1999, 99, 2205-2218.
67. Liu, S.; Edwards, D. S.; Harris, A. R.; Singh, P. R. Tc-99mlabeling kinetics of four thiol-containing chelators and 2-hydrazinopyridine: Factors influencing their radiolabeling efficiency. Appl Radiat Isotopes, 1997, 48, 1103-1111.
68. Miao, Y. B.; Quinn, T. P. Alpha-melanocyte stimulating hormone peptide-targeted melanoma imaging. Front Biosci, 2007, 12, 4514-4524.
69. 99mTc]technetium depreotide: a somatostatin receptor binding tumor imaging agent. J Med Chem, 2007, 50, 4295-4303.
70. 131I]o-iodohippurate. J Nucl Med, 1982, 23, 592-598.
71. Fritzberg, A. R.; Kasina, S.; Eshima, D.; Johnson, D. L. Synthesis and biological evaluation of technetium-99m MAG3 as a hippuran replacement. J Nucl Med, 1986, 27, 111-116.
72. Noll, B.; Johannsen, B.; Muenze, R.; et al. Two-component kit with nonradioactive precursor for the preparation of an enantiomeric form of the kidney function diagnostic agent, Technetium-99mlabeled mercaptoacetyltriglycine. Eur Pat Appl, 1991, EP 427,360.
73. Brandau, W.; Bubeck, B.; Eisenhut, M.; Taylor, D. M. Technetium-99m Labeled Renal-Function and Imaging Agents.3. Synthesis of Tc-99m-MAG3 and Biodistribution of by-Products. Appl Radiat Isotopes, 1988, 39, 121-129.
74. 99mTc-MAG3-Hsa as Possible Blood-Pool Agents. Nucl Med Commun, 1995, 16, 942-957.
75. Visser, G. W. M.; Gerretsen, M.; Herscheid, J. D. M.; Snow, G. B.; Vandongen, G. Labeling of Monoclonal-Antibodies with Re-186 Using the MAG3 Chelate for Radioimmunotherapy of Cancer-a Technical Protocol. J Nucl Med, 1993, 34, 1953-1963.
76. Ram, S.; Buchsbaum, D. J. A Peptide-Based Bifunctional Chelating Agent for Tc-99m-Labeling and Re-186-Labeling of Monoclonal-Antibodies. Cancer, 1994, 73, 769-773.
77. Lister-James, J.; McBride, W. J.; Buttram, S.; et al. Technetium-99m chelate-containing receptor-binding peptides. In Technetium and Rhenium in Chemistry and Nuclear Medicine, Vol 4. Nicolini M, Bandoli G, Mazzi U (eds): Padova, SG Editoriale, 1995, 269-274.
78. Pearson, D. A.; Lister-James, J.; McBride, W. J.; Wilson, D. M.; Martel, L. J.; Civitello, E. R.; Taylor, J. E.; Moyer, B. R.; Dean, R. T. Somatostatin receptor-binding peptides labeled with technetium-99m: chemistry and initial biological studies. J Med Chem, 1996, 39, 1361-1371.
79. 99TcO] apcitide: a technetium labeled peptide. Inorg Chem, 2004, 43, 2867-2875.
80. Reubi, J. C.; Wenger, S.; Schmuckli-Maurer, J.; Schaer, J. C.; Gugger, M. Bombesin receptor subtypes in human cancers: Detection with the universal radioligand I-125-[D-TYR6, beta-ALA(11), PHE13, NLE14] bombesin(6-14). Clin Cancer Res, 2002, 8, 1139-1146.
81. Nock, B.; Nikolopoulou, A.; Chiotellis, E.; Loudos, G.; Maintas, D.; Reubi, J. C.; Maina, T. [Tc-99m]Demobesin 1, a novel potent bombesin analogue for GRP receptor-targeted tumour imaging. Eur J Nucl Med Mol Imaging, 2003, 30, 247-258.
82. Liu, S. The role of coordination chemistry in the development of target-specific radiopharmaceuticals. Chem Soc Rev, 2004, 33, 445-461.
83. Giblin, M. F.; Jurisson, S. S.; Quinn, T. P. Synthesis and characterization of rhenium-complexed alpha-melanotropin analogs. Bioconjug Chem, 1997, 8, 347-353.
84. Miao, Y.; Whitener, D.; Feng, W.; Owen, N. K.; Chen, J.; Quinn, T. P. Evaluation of the human melanoma targeting properties of radiolabeled alpha-melanocyte stimulating hormone peptide analogues. Bioconjug Chem, 2003, 14, 1177-1184.
85. Chen, J.; Cheng, Z.; Hoffman, T. J.; Jurisson, S. S.; Quinn, T. P. Melanoma-targeting properties of (99m)technetium-labeled cyclic alpha-melanocyte-stimulating hormone peptide analogues. Cancer Res, 2000, 60, 5649-5658.
86. Miao, Y. B.; Owen, N. K.; Fisher, D. R.; Hoffman, T. J.; Quinn, T. P. Therapeutic efficacy of a Re-188-labeled alpha-melanocytestimulating hormone peptide analog in murine and human melanoma-bearing mouse models. J Nucl Med, 2005, 46, 121-129.
87. Miao, Y. B.; Quinn, T. P. Peptide-targeted radionuclide therapy for melanoma. Crit Rev Oncol Hemat, 2008, 67, 213-228.
88. Giblin, M. F.; Wang, N.; Hoffman, T. J.; Jurisson, S. S.; Quinn, T. P. Design and characterization of alpha-melanotropin peptide analogs cyclized through rhenium and technetium metal coordination. Proc Natl Acad Sci U S A, 1998, 95, 12814-12818.
89. Chen, J.; Cheng, Z.; Hoffman, T. J.; Jurisson, S. S.; Quinn, T. P. Melanoma-targeting properties of (99m)technetium-labeled cyclic alpha-melanocyte-stimulating hormone peptide analogues. Cancer Res, 2000, 60, 5649-5658.
90. Chen, J.; Cheng, Z.; Miao, Y.; Jurisson, S. S.; Quinn, T. P. Alphamelanocyte-stimulating hormone peptide analogs labeled with technetium-99m and indium-111 for malignant melanoma targeting. Cancer, 2002, 94 (4 Suppl), 1196-1201.
91. 188Re-labeled alpha-melanocyte stimulating hormone peptide analogs for melanoma therapy. Int J Cancer, 2002, 101, 480-487.
92. Yang, J.; Guo, H.; Gallazzi, F.; Berwick, M.; Padilla, R. S.; Miao, Y. Evaluation of a novel Arg-Gly-Asp-conjugated alphamelanocyte stimulating hormone hybrid peptide for potential melanoma therapy. Bioconjug Chem, 2009, 20, 1634-1642.
93. Dadachova, E.; Moadel, T.; Schweitzer, A. D.; Bryan, R. A.; Zhang, T.; Mints, L.; Revskaya, E.; Huang, X. C.; Ortiz, G.; Nosanchuk, J. S.; Nosanchuk, J. D.; Casadevall, A. Radiolabeled melanin-binding peptides are safe and effective in treatment of human pigmented melanoma in a mouse model of disease. Cancer Biother Radio, 2006, 21, 117-129.
94. Fridkin, G.; Bonasera, T. A.; Litman, P.; Gilon, C. Backbone metal-cyclization: a novel approach for simultaneous peptide cyclization and radiolabeling. Application to the combinatorial synthesis of rhenium-cyclic somatostatin analogs. Nucl Med Biol, 2005, 32, 39-50.
95. Bigott-Hennkens, H. M.; Junnotula, S.; Ma, L.; Gallazzi, F.; Lewis, M. R.; Jurisson, S. S. Synthesis and in vitro evaluation of a rhenium-cyclized somatostatin derivative series. J Med Chem, 2008, 51, 1223-1230.
96. Dannoon, S. F.; Bigott-Hennkens, H. M.; Ma, L.; Gallazzi, F.; Lewis, M. R.; Jurisson, S. S. In vitro structure-activity relationship of Re-cyclized octreotide analogues. Nucl Med Biol, 2010, 37, 527-537.
97. Blower, P. J. Towards molecular imaging and treatment of disease with radionuclides: the role of inorganic chemistry. J Chem Soc-Dalton Trans, 2006, 1705-1711.
98. Yeh, S. M.; Sherman, D. G.; Meares, C. F. A new route to "bifunctional" chelating agents: conversion of amino acids to analogs of ethylenedinitrilotetraacetic acid. Anal Biochem, 1979, 100, 152-159.
99. Hnatowich, D. J.; Mardirossian, G.; Rusckowski, M.; Fogarasi, M.; Virzi, F.; Winnard, P., Jr. Directly and indirectly technetium-99mlabeled antibodies--a comparison of in vitro and animal in vivo properties. J Nucl Med, 1993, 34, 109-119.
100. Fichna, J.; Janecka, A. Synthesis of target-specific radiolabeled peptides for diagnostic imaging. Bioconjug Chem, 2003, 14, 3-17.
101. De Leon-Rodriguez, L. M.; Kovacs, Z. The synthesis and chelation chemistry of DOTA-peptide conjugates. Bioconjug Chem, 2008, 19, 391-402.
102. Struthers, H.; Spingler, B.; Mindt, T. L.; Schibli, R. "Click-to-Chelate": Design and incorporation of triazole-containing metalchelating systems into biomolecules of diagnostic and therapeutic interest. Chem-Eur J, 2008, 14, 6173-6183.
103. Abram, U.; Alberto, R. Technetium and rhenium-Coordination chemistry and nuclear medical applications. J Brazil Chem Soc, 2006, 17, 1486-1500.
104. Meegalla, S. K.; Plossl, K.; Kung, M. P.; Stevenson, D. A.; Mu, M.; Kushner, S.; Liable-Sands, L. M.; Reingold, A. L.; Kung, H. F. Specificity of diastereomers of [Tc-99m]TRODAT-1 as dopamine transporter imaging agents. J Med Chem, 1998, 41, 428-436.
105. 2-Phosphino-Amido Ligand. Inorg Chem, 1995, 34, 1779-1787.
106. 2. Inorg Chem, 1997, 36, 1786-1791.
107. 2OH)2]Cl. Inorg Chem, 1997, 36, 3928-3935.
108. Karacay, H.; McBride, W. J.; Griffiths, G. L.; Sharkey, R. M.; Barbet, J.; Hansen, H. J.; Goldenberg, D. M. Experimental pretargeting studies of cancer with a humanized anti-CEA x murine anti-[In-DTPA] bispecific antibody construct and a Tc-99m-Re-188-labeled peptide. Bioconjug Chem, 2000, 11, 842-854.
109. Maina, T.; Nock, B.; Nikolopoulou, A.; Sotiriou, P.; Loudos, G.; Maintas, D.; Cordopatis, P.; Chiotellis, E. [Tc-99m]demotate, a new Tc-99m-based [Tyr(3)]octreotate analogue for the detection of somatostatin receptor-positive tumours: synthesis and preclinical results. Eur J Nucl Med Mol Img, 2002, 29, 742-753.
110. Thakur, M. L.; Kolan, H.; Li, J.; Wiaderkiewicz, R.; Pallela, V. R.; Duggaraju, R.; Schally, A. V. Radiolabeled somatostatin analogs in prostate cancer. Nucl Med Biol, 1997, 24, 105-113.
111. Zuckman, S. A.; Freeman, G. M.; Troutner, D. E.; Volkert, W. A.; Holmes, R. A.; Van Derveer, D. G.; Barefield, E. K. Preparation and x-ray structure of trans-dioxo(1,4,8,11-tetraazacyclotetradecane) technetium(V) perchlorate hydrate. Inorg Chem, 1981, 20, 2386-2389.
112. +. Inorg Chem, 1982, 21, 2037-2040.
113. +. Inorg Chem, 1988, 27, 4127-4130.
114. 6) (Cyclam = 1,4,8,11-Tetraazacyclotetradecane). Inorg Chem, 1992, 31, 2595-2598.
115. Nock, B. A.; Nikolopoulou, A.; Galanis, A.; Cordopatis, P.; Waser, B.; Reubi, J. C.; Maina, T. Potent Bombesin-like peptides for GRPreceptor targeting of tumors with Tc-99m: A preclinical study. J Med Chem, 2005, 48, 100-110.
116. Guhlke, S.; Schaffland, A.; Zamora, P. O.; Sartor, J.; Diekmann, D.; Bender, H.; Knapp, F. F.; Biersack, H. J. Re-188-and Tc-99m-MAG3 as prosthetic groups for labeling amines and peptides: Approaches with pre-and postconjugate labeling. Nucl Med Biol, 1998, 25, 621-631.
117. 3]octreotide. Bioconjug Chem, 1999, 10, 701-702.
118. Lister-James, J.; Knight, L. C.; Maurer, A. H.; Bush, L. R.; Moyer, B. R.; Dean, R. T. Thrombus Imaging with a Technetium-99m-Labeled, Activated Platelet Receptor-Binding Peptide. J Nucl Med, 1996, 37, 775-781.
119. Lebtahi, R.; Le Cloirec, J.; Houzard, C.; Daou, D.; Sobhani, I.; Sassolas, G. V.; Mignon, M.; Bourguet, P.; Le Guludec, D. Detection of neuroendocrine tumors: Tc-99m-P829 scintigraphy compared with In-111-pentetreotide scintigraphy. J Nucl Med, 2002, 43, 889-895.
120. Caveliers, V.; Goodbody, A. E.; Tran, L. L.; Peers, S. H.; Thornback, J. R.; Bossuyt, A. Evaluation of Tc-99m-RP128 as a potential inflammation imaging agent: Human dosimetry and first clinical results. J Nucl Med, 2001, 42, 154-161.
121. Vanderheyden, J. L.; Liu, G. Z.; He, J.; Patel, B.; Tait, J. F.; Hnatowich, D. J. Evaluation of Tc-99m-MAG3-annexin V: influence of the chelate on in vitro and in vivo properties in mice. Nucl Med Biol, 2006, 33, 135-144.
122. Vanderheyden, J. L.; Liu, G.; He, J.; Patel, B.; Hnatowich, D. J. A comparison in normal mice of Annexin V radiolabeled with Tc-99m via HYNIC/tricine and MAG3. J Nucl Med, 2003, 44, 311p-311p.
123. 2 chelate conjugated to the antimicrobial peptide UBI 29-41. Nucl Med Biol, 2004, 31, 503-509.
124. Blankenberg, F.; Ohtsuki, K.; Strauss, H. W. Dying a thousand deaths-Radionuclide imaging of apoptosis. Q J Nucl Med, 1999, 43, 170-176.
125. Pallela, V. R.; Thakur, M. L.; Chakder, S.; Rattan, S. Tc-99mlabeled vasoactive intestinal peptide receptor agonist: Functional studies. J Nucl Med, 1999, 40, 352-360.
126. Baidoo, K. E.; Lin, K. S.; Zhan, Y. G.; Finley, P.; Scheffel, U.; Wagner, H. N. Design, synthesis, and initial evaluation of highaffinity technetium bombesin analogues. Bioconjug Chem, 1998, 9, 218-225.
127. Lin, K. S.; Baidoo, K. E.; Luu, A. N.; Chen, M. K.; Wagner, H. N. In vivo evaluation of new Tc-99m labeled bombesin analogs for tumor imaging. J Nucl Med, 2002, 43, 93p-93p.
128. Lin, K. S.; Luu, A.; Baidoo, K. E.; Hashemzadeh-Gargari, H.; Chen, M. K.; Brenneman, K.; Pili, R.; Pomper, M.; Wagner, H. N. A new high affinity technetium-99m-bombesin analogue with low abdominal accumulation. Bioconjug Chem, 2005, 16, 43-50.
129. Thakur, M. L.; Marcus, C. S.; Saeed, S.; Pallela, V.; Minami, C.; Diggles, L.; Pham, H. L.; Ahdoot, R.; Kalinowski, E. A.; Moody, T. Imaging tumors in humans with Tc-99m-VIP. Ann Ny Acad Sci, 2000, 921, 37-44.
130. 3]octreotide: An intrapatient comparison of two novel technetium-99m labeled tracers for somatostatin receptor scintigraphy. Cancer Biother Radio, 2004, 19, 73-79.
131. 99mTc-Demotate 1: first data in tumour patients-results of a pilot/phase I study. Eur J Nucl Med Mol Imaging, 2003, 30, 1211-1219.
132. Gabriel, M.; Maina, T.; Nock, B.; Cordopatis, P.; Moncayo, R.; Decristoforo, C. First experience with Tc-99m-Demotate 1 in patients in comparison with Tc-99m-EDDA/HYNIC-TOC. Cancer Biother Radio, 2003, 18, 285-286.
133. Maina, T.; Nock, B. A.; Zhang, H. W.; Nikolopoulou, A.; Waser, B.; Reubi, J. C.; Maecke, H. R. Species differences of bombesin analog interactions with GRP-R define the choice of animal models in the development of GRP-R-targeting drugs. J Nucl Med, 2005, 46, 823-830.
134. Cescato, R.; Maina, T.; Nock, B.; Nikolopoulou, A.; Charalambidis, D.; Piccand, V.; Reubi, J. C. Bombesin receptor antagonists may be preferable to agonists for tumor targeting. J Nucl Med, 2008, 49, 318-326.
135. Nock, B. A.; Maina, T.; Behe, M.; Nikolopoulou, A.; Gotthardt, M.; Schmitt, J. S.; Behr, T. M.; Macke, H. R. CCK-2/gastrin receptor-targeted tumor imaging with Tc-99m-labeled minigastrin analogs. J Nucl Med, 2005, 46, 1727-1736.
136. Breeman, W. A. P.; Froberg, A. C.; de Blois, E.; van Gameren, A.; Melis, M.; de Jong, M.; Maina, T.; Nock, B. A.; Erion, J. L.; Macke, H. R.; Krenning, E. P. Optimised labeling, preclinical and initial clinical aspects of CCK-2 receptor-targeting with 3 radiolabeled peptides. Nucl Med Biol, 2008, 35, 839-849.
137. Froberg, A. C.; de Jong, M.; Nock, B. A.; Breeman, W. A. P.; Erion, J. L.; Maina, T.; Verdijsseldonck, M.; de Herder, W. W.; van der Lugt, A.; Kooij, P. P. M.; Krenning, E. P. Comparison of three radiolabelled peptide analogues for CCK-2 receptor scintigraphy in medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging, 2009, 36, 1265-1272.
138. Nock, B. A.; Nikolopoulou, A.; Reubi, J. C.; Maes, V.; Conrath, P.; Tourwe, D.; Maina, T. Toward stable N-4-modified neurotensins for NTS1-receptor-targeted tumor imaging with Tc-99m. J Med Chem, 2006, 49, 4767-4776.
139. Maina, T.; Nikolopoulou, A.; Stathopoulou, E.; Galanis, A. S.; Cordopatis, P.; Nock, B. A. [Tc-99m]Demotensin 5 and 6 in the NTS1-R-targeted imaging of tumours: synthesis and preclinical results. Eur J Nucl Med Mol Imaging, 2007, 34, 1804-1814.
140. 2-BFCA). Nucl Med Biol, 2002, 29, 83-89.
141. Gali, H.; Hoffman, T. J.; Sieckman, G. L.; Owen, N. K.; Katti, K. V.; Volkert, W. A. Synthesis, characterization, and labeling with Tc-99m/Re-188 of peptide conjugates containing a dithiabisphosphine chelating agent. Bioconjug Chem, 2001, 12, 354-363.
142. Safavy, A.; Buchsbaum, D. J.; Khazaeli, M. B. Synthesis of N-[Tris [2-[N-(Benzyloxy)Amino]Carbonyl]Ethyl]Methyl]Succinamic Acid, Trisuccin-Hydroxamic Acid-Derivatives as a New Class of Bifunctional Chelating-Agents. Bioconjug Chem, 1993, 4, 194-198.
143. Safavy, A.; Sanders, A.; Qin, H. Y.; Buchsbaum, D. J. Conjugation of unprotected trisuccin, N-[tris[2-[(N-hydroxyamino)carbonyl] ethyl]methyl] succinamic acid, to monoclonal antibody CC49 by an improved active ester protocol. Bioconjug Chem, 1997, 8, 766-771.
144. Safavy, A.; Khazaeli, M. B.; Mayo, M. S.; Buchsbaum, D. J. Synthesis, rhenium-188 labeling and biodistribution studies of a phenolic ester derivative of trisuccin. Cancer Biother Radio, 1997, 12, 375-384.
145. Safavy, A.; Khazaeli, M. B.; Kirk, M.; Coward, L.; Buchsbaum, D. J. Further studies on the protein conjugation of hydroxamic acid bifunctional chelating agents: Group-specific conjugation at two different loci. Bioconjug Chem, 1999, 10, 18-23.
146. Safavy, A.; Khazaeli, M. B.; Qin, H. Y.; Buchsbaum, D. J. Synthesis of bombesin analogues for radiolabeling with rhenium-188. Cancer, 1997, 80, 2354-2359.
147. 2 conjugates in athymic nude mice bearing intraperitoneal colon cancer xenografts. Clin Cancer Res, 1999, 5, 2994s-3000s.
148. King, T. J.; Harrison, P. G. Crystal and molecular structure of triphenyltin N-benzoyl-N-phenylhydroxamate. J Chem Soc, Chem Com, 1972, 13, 815-816.
149. Heinrich, T. K.; Kraus, W.; Pietzsch, H.-J.; Smuda, C.; Spies, H. Novel Rhenium Chelate System Derived from Dimercaptosuccinic Acid for the Selective Labeling of Biomolecules. Inorg Chem, 2005, 44, 9930-9937.
150. Blower, P. J.; Dilworth, J. R.; Maurer, R. I.; Mullen, G. D.; Reynolds, C. A.; Zheng, Y. Towards new transition metal-based hypoxic selective agents for therapy and imaging. J Inorg Biochem, 2001, 85, 15-22.
151. 99mTc: a reflection on technetium core structures and a strategy for new chelate design. Nucl Med Biol, 2005, 32, 1-20.
152. Liu, S. 6-hydrazinonicotinamide derivatives as bifunctional coupling agents for Tc-99m-labeling of small biomolecules. Top Curr Chem, 2005, 252, 117-153.
153. 3). Polyhedron, 1988, 7, 171-185.
154. yNNR)} Core and Their Relationship to Radiolabeled Organohydrazine-Derivatized Chemotactic Peptides with Diagnostic Applications. Inorg Chem, 1998, 37, 2701-2716.
155. 3). Inorg Chim Acta, 1998, 279, 206-209.
156. 2. Inorg Chim Acta, 1998, 271, 191-194.
157. HirschKuchma, M.; Nicholson, T.; Davison, A.; Jones, A. G. Group 7 'organohydrazide' chemistry: classification of ligand type based on crystal structural data. J Chem Soc-Dalton Trans, 1997, 18, 3189-3192.
158. HirschKuchma, M.; Nicholson, T.; Davison, A.; Davis, W. M.; Jones, A. G. Synthesis and characterization of rhenium(III) and technetium(III) organohydrazide chelate complexes. Reactions of 2-hydrazinopyridine with complexes of rhenium and technetium. Inorg Chem, 1997, 36, 3237-3241.
159. HirschKuchma, M.; Nicholson, T.; Davison, A.; Davis, W. M.; Jones, A. G. The synthesis and characterization of technetium and rhenium hydrazinopyrimidine chelate complexes. J Chem Soc-Dalton Trans, 1997, 18, 3185-3188.
160. 4N). Inorg Chim Acta, 1996, 252, 427-430.
161. 4N). Inorg Chim Acta, 1996, 252, 421-426.
162. Ono, M.; Arano, Y.; Uehara, T.; Fujioka, Y.; Ogawa, K.; Namba, S.; Mukai, T.; Nakayama, M.; Saji, H. Intracellular metabolic fate of radioactivity after injection of technetium-99m-labeled hydrazino nicotinamide derivatized proteins. Bioconjug Chem, 1999, 10, 386-394.
163. Ono, M.; Arano, Y.; Mukai, T.; Fujioka, Y.; Ogawa, K.; Uehara, T.; Saga, T.; Konishi, J.; Saji, H. Tc-99m-HYNIC-derivatized ternary ligand complexes for Tc-99m-labeled polypeptides with low in vivo protein binding. Nucl Med Biol, 2001, 28, 215-224.
164. 3]octreotide. Bioconjug Chem, 1999, 10, 431-438.
165. Decristoforo, C.; Mather, S. J. 99m-Technetium-labelled peptide-HYNIC conjugates: effects of lipophilicity and stability on biodistribution. Nucl Med Biol, 1999, 26, 389-396.
166. Kainz, H.; Bale, R.; Donnemiller, E.; Gabriel, M.; Kovacs, P.; Decristoforo, C.; Moncayo, R. Image fusion analysis of Tc-99m-HYNIC-octreotide scintigraphy and CT/MRI in patients with thyroid-associated orbitopathy: the importance of the lacrimal gland. Eur J Nucl Med Mol Imaging, 2003, 30, 1155-1159.
167. Cwikla, J. B.; Mikolajczak, R.; Pawlak, D.; Buscombe, J. R.; Nasierowska-Guttmejer, A.; Bator, A.; Maecke, H. R.; Walecki, J. Initial direct comparison of Tc-99m-TOC and Tc-99m-TATE in identifying sites of disease in patients with proven GEP NETs. J Nucl Med, 2008, 49, 1060-1065.
168. Decristoforo, C.; Mather, S. J.; Cholewinski, W.; Donnemiller, E.; Riccabona, G.; Moncayo, R. Tc-99m-EDDA/HYNIC-TOC: a new Tc-99-labelled radiopharmaceutical for imaging somatostatin receptor-positive tumours: first clinical results and intra-patient comparison with In-111-labelled octreotide derivatives. Eur J Nucl Med, 2000, 27, 1318-1325.
169. 1-octreotide. Eur J Nucl Med, 2000, 27, 628-637.
170. 2 with favorable properties for SPECT imaging of colon cancer. Bioconjug Chem, 2008, 19, 1170-1178.
171. 99mTc-HYNIC Annexin-V imaging of primary head and neck carcinoma. Nucl Med Commun, 2004, 25, 259-263.
172. 99mTc-HYNIC annexin V uptake to microvessel density, FasL and MMP-9 expression, and the number of tumourinfiltrating lymphocytes in head and neck carcinoma. Eur J Nucl Med Mol Imaging, 2004, 31, 1016-1021.
173. Luo, Q. Y.; Wang, F.; Zhang, Z. Y.; Zhang, Y.; Lu, H. K.; Sun, S. H.; Zhu, R. S. Preparation and bioevaluation of Tc-99m-HYNICannexin B1 as a novel radioligand for apoptosis imaging. Apoptosis, 2008, 13, 600-608.
174. 1]-minigastrin. Bioconjug Chem, 2004, 15, 864-871.
175. Laverman, P.; Behe, M.; Oyen, W. J. G.; Willems, P. H. G. M.; Corstens, F. H. M.; Behr, T. M.; Boerman, O. C. Two technetium-99m-labeled cholecystokinin-8 (CCK8) peptides for scintigraphic imaging of CCK receptors. Bioconjug Chem, 2004, 15, 561-568.
176. 99mTc]HYNIC-RGD for imaging integrin alphavbeta3 expression. Nucl Med Biol, 2006, 33, 945-952.
177. Liu, S.; He, Z.; Hsieh, W. Y.; Kim, Y. S.; Jiang, Y. Impact of PKM linkers on biodistribution characteristics of the Tc-99m-labeled cyclic RGDfK dimer. Bioconjug Chem, 2006, 17, 1499-1507.
178. Su, Z. F.; Liu, G.; Gupta, S.; Zhu, Z.; Rusckowski, M.; Hnatowich, D. J. In vitro and in vivo evaluation of a Technetium-99mlabeled cyclic RGD peptide as a specific marker of alpha(V) beta(3) integrin for tumor imaging. Bioconjug Chem, 2002, 13, 561-570.
179. Liu, S.; Hsieh, W. Y.; Jiang, Y.; Kim, Y. S.; Sreerama, S. G.; Chen, X. Y.; Jia, B.; Wang, F. Evaluation of a Tc-99m-labeled cyclic RGD tetramer for noninvasive imaging integrin alpha(v)beta(3)-positive breast cancer. Bioconjug Chem, 2007, 18, 438-446.
180. Liu, S.; Kim, Y. S.; Hsieh, W. Y.; Sreerama, S. G. Coligand effects on the solution stability, biodistribution and metabolism of the Tc-99m-labeled cyclic RGDfK tetramer. Nucl Med Biol, 2008, 35, 111-121.
181. Cornelissen, B.; Kersemans, V.; Burvenich, I.; Oltenfreiter, R.; Vanderheyden, J. L.; Boerman, O.; Vandewiele, C.; Slegers, G. Synthesis, biodistribution and effects of farnesyltransferase inhibitor therapy on tumour uptake in mice of Tc-99m labelled epidermal growth factor. Nucl Med Commun, 2005, 26, 147-153.
182. Babaei, M. H.; Almqvist, Y.; Orlova, A.; Shafii, M.; Kairemo, K.; Tolmachev, V. [Tc-99m] HYNIC-hEGF, a potential agent for imaging of EGF receptors in vivo: Preparation and pre-clinical evaluation. Oncol Rep, 2005, 13, 1169-1175.
183. Blankenberg, F. G.; Mandl, S.; Cao, Y. A.; O'Connell-Rodwell, C.; Contag, C.; Mari, C.; Gaynutdinov, T. I.; Vanderheyden, J. L.; Backer, M. V.; Backer, J. M. Tumor imaging using a standardized radiolabeled adapter protein docked to vascular endothelial growth factor. J Nucl Med, 2004, 45, 1373-1380.
184. Zinn, K. R.; Kelpke, S.; Chaudhuri, T. R.; Sugg, T.; Mountz, J. M.; Thompson, J. A. Imaging Tc-99m-labeled FGF-1 targeting in rats. Nucl Med Biol, 2000, 27, 407-414.
185. Annovazzi, A.; D'Alessandria, C.; Bonanno, E.; Mather, S. J.; Cornelissen, B.; van de Wiele, C.; Dierckx, R. A.; Mattei, M.; Palmieri, G.; Scopinaro, F.; Signore, A. Synthesis of Tc-99m-HYNIC-interleukin-12, a new specific radiopharmaceutical for imaging T lymphocytes. Eur J Nucl Med Mol Imaging, 2006, 33, 474-482.
186. Gratz, S.; Rennen, H. J.; Boerman, O. C.; Oyen, W. J.; Corstens, F. H. Rapid imaging of experimental colitis with (99m)Tc-interleukin-8 in rabbits. J Nucl Med, 2001, 42, 917-923.
187. Rennen, H. J. J. M.; Boerman, O. C.; Oyen, W. J. G.; Corstens, F. H. M. Kinetics of Tc-99m-Labeled interleukin-8 in experimental inflammation and infection. J Nucl Med, 2003, 44, 1502-1509.
188. Fischman, A. J.; Rauh, D.; Solomon, H.; Babich, J. W.; Tompkins, R. G.; Kroon, D.; Strauss, H. W.; Rubin, R. H. In-Vivo Bioactivity and Biodistribution of Chemotactic Peptide Analogs in Nonhuman-Primates. J Nucl Med, 1993, 34, 2130-2134.
189. Claessens, R. A.; Boerman, O. C.; Koenders, E. B.; Oyen, W. J.; van der Meer, J. W.; Corstens, F. H. Technetium-99m labelled hydrazinonicotinamido human non-specific polyclonal immunoglobulin G for detection of infectious foci: a comparison with two other technetium-labelled immunoglobulin preparations. Eur J Nucl Med, 1996, 23, 414-421.
190. Larsen, S. K.; Solomon, H. F.; Caldwell, G.; Abrams, M. J. [Tc-99m]Tricine-a Useful Precursor Complex for the Radiolabeling of Hydrazinonicotinate Protein Conjugates. Bioconjug Chem, 1995, 6, 635-638.
191. Liu, S.; Edwards, D. S.; Looby, R. J.; Harris, A. R.; Poirier, M. J.; Barrett, J. A.; Heminway, S. J.; Carroll, T. R. Labeling a hydrazino nicotinamide-modified cyclic IIb/IIIa receptor antagonist with Tc-99m using aminocarboxylates as coligands. Bioconjug Chem, 1996, 7, 63-71.
192. Liu, G.; Wescott, C.; Sato, A.; Wang, Y.; Zhu, Z.; Rusckowski, M.; Hnatowich, D. J. Investigations into the stability of Tc-99m-Hynic(tricine)-peptide complexes. J Nucl Med, 2001, 42, 20p-21p.
193. Kim, E. M.; Jeong, H. J.; Heo, Y. J.; Moon, H. B.; Bom, H. S.; Kim, C. G. Intratumoral injection of Re-188 labeled cationic polyethylenimine conjugates: A preliminary report. J Korean Med Sci, 2004, 19, 647-651.
194. 3]octreotide (Tc-99m-EDDA/HYNIC-TOC). J Labelled Compd Rad, 2003, 46, 307-318.
195. Edwards, D. S.; Liu, S.; Barrett, J. A.; Harris, A. R.; Looby, R. J.; Ziegler, M. C.; Heminway, S. J.; Carroll, T. R. New and versatile ternary ligand system for technetium radiopharmaceuticals: Water soluble phosphines and tricine as coligands in labeling a hydrazinonicotinamide-modified cyclic glycoprotein IIb/IIIa receptor antagonist with Tc-99m. Bioconjug Chem, 1997, 8, 146-154.
196. Barrett, J. A.; Crocker, A. C.; Damphousse, D. J.; Heminway, S. J.; Liu, S.; Edwards, D. S.; Lazewatsky, J. L.; Kagan, M.; Mazaika, T. J.; Carroll, T. R. Biological evaluation of thrombus imaging agents utilizing water soluble phosphines and tricine as coligands when used to label a hydrazinonicotinamide-modified cyclic glycoprotein IIb/IIIa receptor antagonist with Tc-99m. Bioconjug Chem, 1997, 8, 155-160.
197. Liu, S.; Edwards, D. S.; Harris, A. R. A novel ternary ligand system for Tc-99m-labeling of hydrazino nicotinamide-modified biologically active molecules using imine-N-containing heterocycles as coligands. Bioconjug Chem, 1998, 9, 583-595.
198. Liu, S.; Ziegler, M. C.; Edwards, D. S. Radio-LC-MS for the characterization of Tc-99m-labeled Bioconjugs. Bioconjug Chem, 2000, 11, 113-117.
199. Line, B. R.; Crane, P.; Lazewatsky, J.; Barrett, J. A.; Cloutier, D.; Kagan, M.; Lukasiewicz, R.; Holmes, R. A. Phase I trial of DMP444, a new thrombus imaging agent. J Nucl Med, 1996, 37, 458-458.
200. Line, B. R.; Seabold, J. E.; Edell, S. L.; Weiland, F. L.; Heit, J. A.; Crane, P. D.; Widner, P. J.; Haber, S. B. Preliminary diagnostic results with DMP444, a new thrombus imaging agent. J Nucl Med, 1998, 39, 218p-218p.
201. Mitchel, J.; Waters, D.; Lai, T. J.; White, M.; Alberghini, T.; Salloum, A.; Knibbs, D.; Li, D. D.; Heller, G. V. Identification of coronary thrombus with a IIb/IIIa platelet inhibitor radiopharmaceutical, technetium-99m DMP444: A canine model. Circulation, 2000, 101, 1643-1646.
202. Klem, J. A.; Schaffer, J. V.; Crane, P. D.; Barrett, J. A.; Henry, G. A.; Canestri, L.; Ezekowitz, M. D. Detection of deep venous thrombosis by DMP444, a platelet IIb/IIIa antagonist: A preliminary report. J Nucl Cardiol, 2000, 7, 359-364.
203. 2 formulation for RP444, a new radiopharmaceutical for thrombus imaging. J Pharm Sci, 2001, 90, 114-123.
204. Purohit, A.; Liu, S.; Casebier, D.; Edwards, D. S. Phosphinecontaining HYNIC derivatives as potential bifunctional chelators for Tc-99m-labeling of small biomolecules. Bioconjug Chem, 2003, 14, 720-727.
205. 2], a Complex with a Hydrazido(2-) Ligand with a Large Angular Distortion. Inorg Chem, 1985, 24, 2594-2595.
206. 2]. Polyhedron, 1987, 6, 1577-1585.
207. 7]. Inorg Chem, 1988, 27, 241-250.
208. 2. Inorg Chim Acta, 1991, 185, 7-15.
209. Abrams, M. J.; Juweid, M.; Tenkate, C. I.; Schwartz, D. A.; Hauser, M. M.; Gaul, F. E.; Fuccello, A. J.; Rubin, R. H.; Strauss, H. W.; Fischman, A. J. Technetium-99m-Human Polyclonal Igg Radiolabeled Via the Hydrazino Nicotinamide Derivative for Imaging Focal Sites of Infection in Rats. J Nucl Med, 1990, 31, 2022-2028.
210. 2O. J Chem Soc-Dalton Trans, 1993, 897-904.
211. Archer, C. M.; Dilworth, J. R.; Jobanputra, P.; Thompson, R. M.; Mcpartlin, M.; Povey, D. C.; Smith, G. W.; Kelly, J. D. Development of New Technetium Cores Containing Technetium Nitrogen Multiple Bonds-Synthesis and Characterization of Some Diazenido-Complexes, Hydrazido-Complexes and Imido-Complexes of Technetium. Polyhedron, 1990, 9, 1497-1502.
212. Waibel, R.; Alberto, R.; Willuda, J.; Finnern, R.; Schibli, R.; Stichelberger, A.; Egli, A.; Abram, U.; Mach, J. P.; Pluckthun, A.; Schubiger, P. A. Stable one-step technetium-99m labeling of Histagged recombinant proteins with a novel Tc(I)-carbonyl complex. Nat Biotechnol, 1999, 17, 897-901.
213. Egli, A.; Alberto, R.; Tannahill, L.; Schibli, R.; Abram, U.; Schaffland, A.; Waibel, R.; Tourwe, D.; Jeannin, L.; Iterbeke, K.; Schubiger, P. A. Organometallic Tc-99m-aquaion labels peptide to an unprecedented high specific activity. J Nucl Med, 1999, 40, 1913-1917.
214. + in bioorganometallic chemistry: Design, structure, and in vitro affinity of a 5-HT1A receptor ligand labeled with Tc-99m. J Am Chem Soc, 1999, 121, 6076-6077.
215. 3]. Trans Metal Chem, 1997, 22, 597-601.
216. - in aqueous solution and its reaction with a bifunctional ligand. J Am Chem Soc, 1998, 120, 7987-7988.
217. Schibli, R.; La Bella, R.; Alberto, R.; Garcia-Garayoa, E.; Ortner, K.; Abram, U.; Schubiger, P. A. Influence of the denticity of ligand systems on the in vitro and in vivo behavior of Tc-99m(I)-tricarbonyl complexes: A hint for the future functionalization of biomolecules. Bioconjug Chem, 2000, 11, 345-351.
218. + retains biological activity in vitro. Nucl Med Biol, 2001, 28, 243-250.
219. +. J Am Chem Soc, 2001, 123, 3135-3136.
220. + and synthesis of tailor-made bifunctional ligand systems. Bioconjug Chem, 2002, 13, 750-756.
221. +. Chem-Eur J, 2003, 9, 2053-2061.
222. + chemistry: a promising new concept for SPET? Eur J Nucl Med Mol Imaging, 2003, 30, 1299-1302.
223. Alberto, R. New organometallic technetium complexes for radiopharmaceutical imaging Contrast Agents III: Radiopharmaceuticals from Diagnostics to Therapeutics, 2005, 252, 1-44.
224. Schibli, R.; Schubiger, P. A. Current use and future potential of organometallic radiopharmaceuticals. Eur J Nucl Med Mol Imaging, 2002, 29, 1529-1542.
225. 3] (M=Tc-99m, Re) complexes. J Am Chem Soc, 2008, 130, 1554-1555.
226. Bartholoma, M.; Valliant, J.; Maresca, K. P.; Babich, J.; Zubieta, J. Single amino acid chelates (SAAC): a strategy for the design of technetium and rhenium radiopharmaceuticals. Chem Commun, 2009, 493-512.
227. +]G. Bioconjug Chem, 2004, 15, 128-136.
228. 2Me}]Br. Inorg Chem Commun, 2004, 7, 481-484.
229. Stephenson, K. A.; Banerjee, S. R.; Sogbein, O. O.; Levadala, M. K.; McFarlane, N.; Boreham, D. R.; Maresca, K. P.; Babich, J. W.; Zubieta, J.; Valliant, J. F. A new strategy for the preparation of peptide-targeted technetium and rhenium radiopharmaceuticals. The automated solid-phase synthesis, characterization, labeling, and screening of a peptide-ligand library targeted at the formyl peptide receptor. Bioconjug Chem, 2005, 16, 1189-1195.
230. 3 +1 core (M = Tc and Re): Syntheses, characterization, biotinidase stability, and avidin binding. Bioconjug Chem, 2006, 17, 579-589.
231. + (M = Re, Tc) directed towards radiopharmaceutical application. Coordin Chem Rev, 1999, 192, 901-919.
232. Garcia, R.; Xing, Y. H.; Paulo, A.; Domingos, A.; Santos, I. Rhenium(I) tricarbonyl complexes with mercaptoimidazolylborate ligands bearing piperazine fragments. J Chem Soc-Dalton Trans, 2002, 22, 4236-4241.
233. Vitor, R. F.; Alves, S.; Correia, J. D. G.; Paulo, A.; Santos, I. Rhenium(I)-and technetium(I) tricarbonyl complexes anchored by bifunctional pyrazole-diamine and pyrazole-dithioether chelators. J Organom Chem, 2004, 689, 4764-4774.
234. Fernandes, C.; Santos, I. C.; Santos, I.; Pietzsch, H. J.; Kunstler, J. U.; Kraus, W.; Rey, A.; Margaritis, N.; Bourkoula, A.; Chiotellis, A.; Paravatou-Pestsotas, M.; Pirmettis, I. Rhenium and technetium complexes bearing quinazoline derivatives: progress towards a Tc-99m biomarker for EGFR-TK imaging. J Chem Soc-Dalton Trans, 2008, 24, 3215-3225.
235. + moiety (M=Tc-99m, Re): Synthesis, characterization, and biological behavior. Bioconjug Chem, 2005, 16, 438-449.
236. + moiety. Nucl Med Biol, 2006, 33, 625-634.
237. 3-pyrazolyl conjugate of cyclo-(Arg-Gly-Asp-D-Tyr-Lys). Bioconjug Chem, 2007, 18, 530-537.
238. 3-labeled pyrazolyl-alphamelanocyte-stimulating hormone analog conjugate for melanoma targeting. Nucl Med Biol, 2008, 35, 91-99.
239. +: effect of cyclization on tumor-seeking properties. J Biol Inorg Chem, 2008, 13, 449-459.
240. Khan, I. U.; Zwanziger, D.; Bohme, I.; Javed, M.; Naseer, H.; Hyder, S. W.; Beck-Sickinger, A. G. Breast-cancer diagnosis by neuropeptide Y analogues: from synthesis to clinical application. Angew Chem Int Ed Engl, 2010, 49, 1155-1158.
241. 3 bombesin analogues. Nucl Med Biol, 2007, 34, 17-28.
242. 3]-labeled bombesin analogues for improved targeting of gastrin-releasing peptide receptor-positive tumors. Bioconjug Chem, 2008, 19, 2432-2439.
243. Vallejo, E.; Martinez, I.; Tejero, A.; Hernandez, S.; Jimenez, L.; Bialostozky, D.; Sanchez, G.; Ilarraza, H.; Ferro-Flores, G. Clinical Utility of Tc-99m-Labeled Ubiquicidin 29-41 Antimicrobial Peptide for the Scintigraphic Detection of Mediastinitis after Cardiac Surgery. Arch Med Res, 2008, 39, 768-774.
244. Raposinho, P. D.; Correia, J. D.; Oliveira, M. C.; Santos, I. Melanocortin-1 receptor-targeting with radiolabeled cyclic alphamelanocyte-stimulating hormone analogs for melanoma imaging. Biopolymers, 2010, 94, 820-829.
245. 99mTc-labeled glucosamino RGD and effect of paclitaxel therapy. J Nucl Med, 2006, 47, 2000-2007.
246. Decristoforo, C.; Santos, I.; Pietzsch, H. J.; Kuenstler, J. U.; Duatti, A.; Smith, C. J.; Rey, A.; Alberto, R.; Von Guggenberg, E.; Haubner, R. Comparison of in vitro and in vivo properties of [Tc-99m]cRGD peptides labeled using different novel Tc-cores. Q J Nucl Med Mol Im, 2007, 51, 33-41.
247. Vangestel, C.; Peeters, M.; Oltenfreiter, R.; D'Asseler, Y.; Staelens, S.; Van Steenkiste, M.; Philippe, J.; Kusters, D.; Reutelingsperger, C.; Van Damme, N.; Van de Wiele, C. In vitro and in vivo evaluation of [Tc-99m]-labeled tricarbonyl His-annexin A5 as an imaging agent for the detection of phosphatidylserine-expressing cells. Nucl Med Biol, 2010, 37, 965-975.
248. 3 for improved imaging of apoptosis in vivo. Bioorgan Med Chem, 2010, 18, 1356-1363.
249. Biechlin, M. L.; Bonmartin, A.; Gilly, F. N.; Fraysse, M.; d'Hardemare, A. D. Radiolabeling of annexin A5 with Tc-99m: comparison of HYNIC-Tc vs. iminothiolane-Tc-tricarbonyl conjugates. Nucl Med Biol, 2008, 35, 679-687.
250. Blankenberg, F. G.; Tait, J. F.; Blankenberg, T. A.; Post, A. M.; Strauss, H. W. Imaging macrophages and the apoptosis of granulocytes in a rodent model of subacute and chronic abscesses with radiolabeled monocyte chemotactic peptide-1 and annexin V. Eur J Nucl Med, 2001, 28, 1384-1393.
251. Blauenstein, P.; Garayoa, E. G.; Ruegg, D.; Blanc, A.; Tourwe, D.; Beck-Sickinger, A.; Schubiger, P. A. Improving the tumor uptake of Tc-99m-labeled neuropeptides using stabilized peptide analogues. Cancer Biother Radio, 2004, 19, 181-188.
252. 99mTc-labeled neurotensin peptide 8-13. Nucl Med Biol, 2006, 33, 505-512.
253. 99mTc-labeled neurotensin analogues with optimized biodistribution properties. J Med Chem, 2006, 49, 1833-1836.
254. 99mTc-tricarbonyl. Biopolymers, 2008, 90, 707-712.
255. 99mTc-labeled neuropeptide Y analogues as potential tumor imaging agents. Bioconjug Chem, 2001, 12, 1028-1034.
256. +. Nucl Med Commun, 2005, 26, 453-458.
257. 188Re tricarbonyl provides improved in vitro and in vivo stability to reoxidation. Nucl Med Commun, 2004, 25, 731-736.
258. 2]: syntheses, radiolabeling and in vitro/in vivo GRP receptor targeting studies. Anticancer Res, 2003, 23, 63-70.
259. 3. Cancer Res, 2003, 63, 4082-4088.
260. Muller, C.; Schubiger, P. A.; Schibli, R. Isostructural folate conjugates radiolabeled with the matched pair Tc-99m/Re-188: a potential strategy for diagnosis and therapy of folate receptorpositive tumors. Nucl Med Biol, 2007, 34, 595-601.
261. + for the labeling of biomolecules. Bioconjug Chem, 2006, 17, 223-225.
262. 188Re at high labeling efficiency and specific radioactivity for tumor pretargeting. Appl Radiat Isot, 2006, 64, 971-978.
263. van Gog, F. B.; Visser, G. W.; Stroomer, J. W.; Roos, J. C.; Snow, G. B.; van Dongen, G. A. High dose rhenium-186-labeling of monoclonal antibodies for clinical application: pitfalls and solutions. Cancer, 1997, 80, 2360-2370.
264. Bryan, J. C.; Burrell, A. K.; Miller, M. M.; Smith, W. H.; Burns, C. J.; Sattelberger, A. P. Synthesis and Reactivity of Technetium(VII) Imido Complexes. Polyhedron, 1993, 12, 1769-1777.
265. Arterburn, J. B.; Rao, K. V.; Goreham, D. M.; Valenzuela, M. V.; Holguin, M. S.; Hall, K. A.; Ott, K. C.; Bryan, J. C. Functionalized rhenium(V) organoimido complexes as potential radiopharmaceuticals. 2. Synthesis, structural characterization, and reactivity of N-succinimidyl ester derivatives with amines. Organometallics, 2000, 19, 1789-1795.
266. Duatti, A.; Marchi, A.; Pasqualini, R. Formation of the Tc≡N Multiple Bond from the Reaction of Ammonium Pertechnetate with S-Methyl Dithiocarbazate and Its Application to the Preparation of Tc-99m Radiopharmaceuticals. J Chem Soc-Dalton Trans, 1990, 12, 3729-3733.
267. Boschi, A.; Duatti, A.; Uccelli, L. Development of technetium-99m and rhenium-188 radiopharmaceuticals containing a terminal metal-nitrido multiple bond for diagnosis and therapy. Top Curr Chem, 2005, 252, 85-115.
268. Pasqualini, R.; Duatti, A.; Bellande, E.; Comazzi, V.; Brucato, V.; Hoffschir, D.; Fagret, D.; Comet, M. Bis(Dithiocarbamato) Nitrido Tc-99m Radiopharmaceuticals a Class of Neutral Myocardial Imaging Agents. J Nucl Med, 1994, 35, 334-341.
269. 2] [L5=2-(ditolylphosphino)propanethiolato]. Inorg Chem, 1999, 38, 4473-4479.
270. Bolzati, C.; Uccelli, L.; Boschi, A.; Malago, E.; Duatti, A.; Tisato, F.; Refosco, F.; Pasqualini, R.; Piffanelli, A. Synthesis of a novel class of nitrido Tc-99m radiopharmaceuticals with phosphinothiol ligands showing transient heart uptake. Nucl Med Biol, 2000, 27, 369-374.
271. Bolzati, C.; Boschi, A.; Duatti, A.; Prakash, S.; Uccelli, L.; Refosco, F.; Tisato, F.; Bandoli, G. Geometrically controlled selective formation of nitrido technetium(V) asymmetrical heterocomplexes with bidentate ligands. J Am Chem Soc, 2000, 122, 4510-4511.
272. 2+ (PXP = diphosphine ligand). A novel tool for the selective labeling of small molecules. J Am Chem Soc, 2002, 124, 11468-11479.
273. 2+ (PXP = diphosphine ligand). Bioconjug Chem, 2001, 12, 1035-1042.
274. + (M=Tc-99, Re; DTC = dithiocarbamate; PNP = heterodiphosphane). Eur J Inorg Chem, 2004, 9, 1902-1913.
275. 2+ metal fragments (M = Tc, Re; PXP = diphosphine ligand). Inorg Chem, 2004, 43, 8617-8625.
276. Bolzati, C.; Malagò, E.; Boschi, A.; Cagnolini, A.; Porchia, M.; Bandoli, G. Symmetric bis-substituted and asymmetric monosubstituted nitridotechnetium complexes with heterofunctionalized phosphinothiolate ligands. New J Chem, 1999, 23, 807-809.
277. Bolzati, C.; Benini, E.; Cavazza-Ceccato, M.; Cazzola, E.; Malago, E.; Agostini, S.; Tisato, F.; Refosco, F.; Bandoli, G. From symmetrical to asymmetrical nitrido phosphino-thiol complexes: A new class of neutral mixed-ligand Tc-99m compounds as potential brain imaging agents. Bioconjug Chem, 2006, 17, 419-428.
278. Bolzati, C.; Cavazza-Ceccato, M.; Agostini, S.; Tisato, F.; Bandoli, G. Technetium and Rhenium in Five-Coordinate Symmetrical and Dissymmetrical Nitrido Complexes with Alkyl Phosphino-thiol Ligands. Synthesis and Structural Characterization. Inorg Chem, 2008, 47, 11972-11983.
279. Boschi, A.; Bolzati, C.; Uccelli, L.; Duatti, A.; Benini, E.; Refosco, F.; Tisato, F.; Piffanelli, A. A class of asymmetrical nitrido Tc-99m heterocomplexes as heart imaging agents with improved biological properties. Nucl Med Commun, 2002, 23, 689-693.
280. Boschi, A.; Uccelli, L.; Bolzati, C.; Duatti, A.; Sabba, N.; Moretti, E.; Di Domenico, G.; Zavattini, G.; Refosco, F.; Giganti, M. Synthesis and biologic evaluation of monocationic asymmetric Tc-99-Nitride heterocomplexes showing high heart uptake and improved imaging properties. J Nucl Med, 2003, 44, 806-814.
281. Bolzati, C.; Benini, E.; Cazzola, E.; Jung, C.; Tisato, F.; Refosco, F.; Pietzsch, H. J.; Spies, H.; Uccelli, L.; Duatti, A. Synthesis, characterization, and biological evaluation of neutral nitrido technetium(V) mixed ligand complexes containing dithiolates and aminodiphosphines. A novel system for linking technetium to biomolecules. Bioconjug Chem, 2004, 15, 628-637.
282. Baraldi, P. G.; Romagnoli, R.; Duatti, A.; Bolzati, C.; Piffanelli, A.; Bianchi, N.; Mischiati, C.; Gambari, R. Synthesis of hybrid distamycin-cysteine labeled with Tc-99m: a model for a novel class of cancer imaging agents. Bioorg Med Chem Lett, 2000, 10, 1397-1400.
283. 2+ metal fragment: A technetium-nitrido synthon for use with biologically active molecules the N-(2-methoxyphenyl) piperazyl-cysteine analogues as examples. Bioconjug Chem, 2003, 14, 1231-1242.
284. Boschi, A.; Uccelli, L.; Duatti, A.; Bolzati, C.; Refosco, F.; Tisato, F.; Romagnoli, R.; Baraldi, P. G.; Varani, K.; Borea, P. A. Asymmetrical nitrido Tc-99m heterocomplexes as potential imaging agents for benzodiazepine receptors. Bioconjug Chem, 2003, 14, 1279-1288.
285. 2+ metal fragment. Nucl Med Biol, 2007, 34, 511-522.
286. 2+ metal fragment labeled cholecystokinin-8 (CCK8) peptide for CCK-2 receptors imaging: in vitro and in vivo studies. J Pept Sci, 2007, 13, 211-219.
287. Faintuch, B. L.; Teodoro, R.; Duatti, A.; Muramoto, E.; Faintuch, S.; Smith, C. J. Radiolabeled bombesin analogs for prostate cancer diagnosis: preclinical studies. Nucl Med Biol, 2008, 35, 401-411.
288. Mukherjee, A.; Kothari, K.; Toth, G.; Szemenyei, E.; Sarma, H. D.; Kornyei, J.; Venkatesh, M. Tc-99m-labeled annexin V fragments: a potential SPECT radiopharmaceutical for imaging cell death. Nucl Med Biol, 2006, 33, 635-643.
289. Bolzati, C.; Salvarese, N.; Carta, D.; Refosco, F.; Dolmella, A.; Pietzsch, H. J.; Bergmann, R.; Bandoli, G. Synthesis and biological evaluation of new [Tc(N)(PS)]-based mixed-ligand compounds useful in the design of target-specific radiopharmaceuticals: the 2-methoxyphenylpiperazine dithiocarbamate derivatives as an example. J Biolog Inorg Chem, 2011, 16, 137-155.
290. Boschi, A.; Uccelli, L.; Duatti, A.; Colamussi, P.; Cittanti, C.; Filice, A.; Rose, A. H.; Martindale, A. A.; Claringbold, P. G.; Kearney, D.; Galeotti, R.; Turner, H. J.; Giganti, M. A kit formulation for the preparation of Re-188-lipiodol: preclinical studies and preliminary therapeutic evaluation in patients with unresectable hepatocellular carcinoma. Nucl Med Commun, 2004, 25, 983-983.
291. 188Re(N)-based target-specific radiopharmaceuticals. Nucl Med Biol, 2011, 38, 399-415.
292. Boschi, A.; Massi, A.; Uccelli, L.; Pasquali, M.; Duatti, A. PEGylated N-methyl-S-methyl dithiocarbazate as a new reagent for the high-yield preparation of nitrido Tc-99m and Re-188 radiopharmaceuticals. Nucl Med Biol, 2010, 37, 927-934.
293. 3 Tripod Ligands. Angew Chem Int Edit, 1994, 33, 1354-1356.
294. 3 ligand. Inorg Chim Acta, 1995, 240, 465-478.
295. Spies, H.; Fietz, T.; Glaser, M.; Pietzsch, H.-J.; Johannsen, B. The "n+1" concept in the strategy of novel technetium and rhenium tracers. In Technetium and Rhenium in Chemistry and Nuclear Medicine 4. Nicolini, M., and Mazzi, U., Eds. SGEditoriali, Padova, Italy, 1995, 243-246.
296. 3/isocyanide coordination: a new nonpolar technetium chelate system for the design of neutral and lipophilic complexes stable in vivo. Bioconjug Chem, 2001, 12, 538-544.
297. 3/P ('4+1') coordination: Relation of structure with antioxidation stability. Bioconjug Chem, 2005, 16, 634-643.
298. Drews, A.; Pietzsch, H. J.; Syhre, R.; Seifert, S.; Varnas, K.; Hall, H.; Halldin, C.; Kraus, W.; Karlsson, P.; Johnsson, C.; Spies, H.; Johannsen, B. Synthesis and biological evaluation of technetium(III) mixed-ligand complexes with high affinity for the cerebral 5-HT1A receptor and the alpha1-adrenergic receptor. Nucl Med Biol, 2002, 29, 389-398.
299. Kunstler, J. U.; Veerendra, B.; Figueroa, S. D.; Sieckman, G. L.; Rold, T. L.; Hoffman, T. J.; Smith, C. J.; Pietzsch, H. J. Organometallic Tc-99m(III) '4+1' bombesin(7-14) conjugates: Synthesis, radiolabeling, and in vitro/in vivo studies. Bioconjug Chem, 2007, 18, 1651-1661.
300. Dirscherl, G.; Konig, B. The use of solid-phase synthesis techniques for the preparation of peptide-metal complex conjugates. Eur J Org Chem, 2008, 4, 597-634.
301. Mankoff, D. A.; Link, J. M.; Linden, H. M.; Sundararajan, L.; Krohn, K. A. Tumor receptor imaging. J Nucl Med, 2008, 49, 149s-163s.
302. Valliant, J. F.; Cooke, M.; Darwish, A.; Simms, R.; Hicks, J. W.; Causey, P. W.; Adronov, A. Modern ligand design for targeted metallo-radiopharmaceuticals: from radiochemistry through pharmacokinetic optimization. In Technetiun and Other Metals in Chemistry and Medicine, eds Mazzi U. Eckelman W.C. and Volkert W.A. SGEditoriali, Padova, Italy, 2010, 13-24.
303. Mammen, M.; Choi, S. K.; Whitesides, G. M. Polyvalent interactions in biological systems: Implications for design and use of multivalent ligands and inhibitors. Angew Chem Int Edit, 1998, 37, 2755-2794.
304. Vagner, J.; Xu, L. P.; Handl, H. L.; Josan, J. S.; Morse, D. L.; Mash, E. A.; Gillies, R. J.; Hruby, V. J. Heterobivalent Ligands crosslink multiple cell-surface receptors: The human melanocortin-4 and delta-opioid receptors. Angew Chem Int Edit, 2008, 47, 1685-1688.
305. Goel, A.; Baranowska-Kortylewicz, J.; Hinrichs, S. H.; Wisecarver, J.; Pavlinkova, G.; Augustine, S.; Colcher, D.; Booth, B. J. M.; Batra, S. K. Tc-99m-labeled divalent and tetravalent CC49 singlechain Fv's: Novel imaging agents for rapid in vivo localization of human colon carcinoma. J Nucl Med, 2001, 42, 1519-1527.
306. 99mTc-labeling of a hydrazinonicotinamideconjugated vitronectin receptor antagonist useful for imaging tumors. Bioconjug Chem, 2001, 12, 624-629.
307. 177Lu labeling of a DOTA-conjugated vitronectin receptor antagonist useful for tumor therapy. Bioconjug Chem, 2001, 12, 559-568.
308. 177Lu-labeling of a DOTA-conjugated nonpeptide vitronectin receptor antagonist. Bioconjug Chem, 2003, 14, 1030-1037.
309. Janssen, M. L.; Oyen, W. J.; Dijkgraaf, I.; Massuger, L. F.; Frielink, C.; Edwards, D. S.; Rajopadhye, M.; Boonstra, H.; Corstens, F. H.; Boerman, O. C. Tumor targeting with radiolabeled alpha(v)beta(3) integrin binding peptides in a nude mouse model. Cancer Res, 2002, 62, 6146-6151.
310. 18Flabeled dimeric RGD peptide. Mol Imaging, 2004, 3, 96-104.
311. 64Cu-labeled dimeric RGD peptides. Mol Imaging Biol, 2004, 6, 350-359.
312. Poethko, T.; Thumshirn, G.; Hersel, U.; Hauser, A.; Kessler, H.; Schwaiger, M.; Wester, H. J. Multimerization of Integrin Antagonists Allows High Contrast Imaging of Alpha(V)Beta(3) Integrins. J Labelled Compd Rad, 2005, 48, S60-S60.
313. Poethko, T.; Thumshirn, G.; Hersel, U.; Rau, F.; Haubner, R.; Schwaiger, M.; Kessler, H.; Wester, H. J. Improved tumor uptake, tumor retention and tumor/background ratios of pegylated RGDmultimers. J Nucl Med, 2003, 44, 46p-46p.
314. Boturyn, D.; Coll, J. L.; Garanger, E.; Favrot, M. C.; Dumy, P. Template assembled cyclopeptides as multimeric system for integrin targeting and endocytosis. J Am Chem Soc, 2004, 126, 5730-5739.
315. Shi, J.; Wang, L.; Kim, Y. S.; Zhai, S.; Liu, Z.; Chen, X.; Liu, S. Improving tumor uptake and excretion kinetics of 99mTc-labeled cyclic arginine-glycine-aspartic (RGD) dimers with triglycine linkers. J Med Chem, 2008, 51, 7980-7990.
316. Dijkgraaf, I.; Kruijtzer, J. A.; Liu, S.; Soede, A. C.; Oyen, W. J.; Corstens, F. H.; Liskamp, R. M.; Boerman, O. C. Improved targeting of the alpha(v)beta (3) integrin by multimerisation of RGD peptides. Eur J Nucl Med Mol Imaging, 2007, 34, 267-273.